Ultra-Scan's TouchLink Solution Allows CROs to Accurately Identify Patients and Ensure Study Integrity.
Buffalo, NY-June 13, 2006-As federal regulations become stricter, it is important for clinical research organizations (CROs) to take the necessary measurements and precautions to accurately identify study participants and their eligibility for clinical trial participation. Ultra-Scan Corporation, an identity management solutions provider, will showcase its TouchLink Identity Management Software at the Drug Information Association's 42nd Annual Meeting in Philadelphia. Researchers and trial administrators will have the opportunity learn more about this revolutionary technology in support of clinical trials.
Ultra-Scan's TouchLink Identity Management Software offers clinical research organizations an accurate and cost-effective solution for establishing, managing and repeatedly validating subject identity. TouchLink provides standalone or integrated identification utilizing Ultra-Scan's patented ultrasonic fingerprint identification system to quickly and easily enroll and identify a subject population within a single site or across multiple sites and facilities. From screening through post-study follow-up, TouchLink can positively impact study results and enhance subject safety by providing essential identity validation. In turn, this ensures that each authorized subject is properly tested, treated, monitored and reimbursed during clinic and study encounters.
TouchLink is supported by Ultra-Scan's patented Livescan Ultrasonic Identification Systems (LUIS™), a biometric technology that uses ultrasound, high frequency sound waves, to capture high quality fingerprint images across all user populations and operational environments. LUIS can "see through" dirt, newsprint, hand lotions and other common finger contaminants, guaranteeing unsurpassed accuracy, reliability and ease of use.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.